Drug
Icp 322
Icp 322: highest development phase Phase 2, developed by InnoCare Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- InnoCare Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| ICP-322 NCT07236099 | Phase 2 | Prurigo Nodularis (PN) |
Latest
No recent events.
Follow Icp 322 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.